

## ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49  
55129 Mainz - Germany

Phone: +496131/92580  
Fax: +496131/925858  
Internet : www.orgentec.com



Instruction for use  
August 2005



## ORG 5MA Micro-Albumin

Immunometric Enzyme Immunoassay for the quantitative determination of Micro-Albumin in urine

### CONTENTS

NAME AND INTENDED USE  
SUMMARY AND EXPLANATION OF THE TEST  
PRINCIPLE OF THE TEST  
WARNINGS AND PRECAUTIONS  
CONTENTS OF THE KIT  
STORAGE AND STABILITY  
MATERIALS REQUIRED  
SPECIMEN COLLECTION AND HANDLING  
PROCEDURAL NOTES  
PREPARATION OF REAGENTS  
TEST PROCEDURE  
INTERPRETATION OF RESULTS  
PERFORMANCE CHARACTERISTICS  
LIMITATIONS OF PROCEDURE  
INTERFERING SUBSTANCES  
REFERENCES  
INCUBATION SCHEME

### NAME AND INTENDED USE

Micro-Albumin is a competitive solid phase enzyme immunoassay (ELISA) for the quantitative measurement of human albumin in urine. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of Microalbuminuria.

### SUMMARY AND EXPLANATION OF THE TEST

Proteins passing the glomerular basal membrane of the kidney undergo differentiated filtering. The permeability is inversely proportional to the molecular weight (Albumin about 0.6 %, Myoglobin about 75 %). Nevertheless, only minimal quantities of protein are detectable in urine, because big quantities of protein are reabsorbed by the tubuli. Elevated glomerular protein permeability and high tubular plasma protein elimination can be differentiated by measuring the molecular weight distribution of the eliminated proteins.

The pattern of eliminated proteins in urine give information about :

- elevated protein elimination
- differentiation of proteinuria
- prediagnosis of a kidney defect
- glomerular or tubular proteinuria

Diagnostically relevant proteins:

- IgG (150 kD)
- Albumin (66 kD)
- Alpha-1-Microglobulin (33 kD)
- Retinol binding protein (21 kD)
- Beta-2-Microglobulin (12 kD)
- Immunoglobulin light chains (Bence-Jones protein) (22 kD)

Albumin has a relative molecular mass of 66 kD. It is contained in urine at very low concentrations. In case of a very active glomerular filtering process the albumin secretion can arise without an underlying kidney disease. This situation is called "Microalbuminuria". The detection of these small secretion quantities (30 to 150 µg/min or ml) requires very sensitive test-systems<sup>1,6</sup>, i.e. immunological techniques. Physical stress can induce elevated albumin secretion too, without the occurrence of a kidney disease.

In Diabetes, Albumin secretion is a very important parameter for the evaluation of the kidney function. Urine values higher than 25 µg/ml indicate a detrimental kidney function of insulin-dependent<sup>2,3</sup> (type I) and non-insulin-dependent<sup>4,5,6</sup> (type II) diabetic patients. The determination of Albumin is therefore an important diagnostic tool in diabetic nephropathies<sup>1,7,8</sup>.

Indication : Microalbuminuria

### PRINCIPLE OF THE TEST

Highly purified human albumin is bound to microwells. Calibrators, controls and undiluted patient samples are pipetted together with anti-human-Albumin-peroxidase conjugate in the wells. Micro-albumin, if present in diluted urine, will compete with coated albumin for binding of the anti-albumin-conjugate. Washing of the microwells removes unspecific compo-

nents. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue color. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow color is measured photometrically at 450 nm. The amount of colour is inversely proportional to the concentration of albumin present in the original sample.

#### WARNINGS AND PRECAUTIONS

1. All reagents of this kit are strictly intended for in vitro diagnostic use only.
2. Do not interchange kit components from different lots.
3. Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
4. Avoid contact with the TMB (3,3',5,5'-Tetramethyl-benzidine). If TMB comes into contact with skin, wash thoroughly with water and soap.
5. Avoid contact with the Stop Solution which is hydrochloric acid (1 M). If it comes into contact with skin, wash thoroughly with water and seek medical attention.
6. Some kit components (i.e. Controls, Sample buffer and Buffered Wash Solution) contain Sodium Azide as preservative. Sodium Azide ( $\text{NaN}_3$ ) is highly toxic and reactive in pure form. At the product concentrations (0.09%), though not hazardous. Despite the classification as non-hazardous, we strongly recommend using prudent laboratory practices (see 8., 9., 10.).
7. Some kit components contain Proclin 300 as preservative. When disposing reagents containing Proclin 300, flush drains with copious amounts of water to dilute the components below active levels.
8. Wear disposable gloves while handling specimens or kit reagents and wash hands thoroughly afterwards.
9. Do not pipette by mouth.
10. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled.
11. Avoid contact between the buffered Peroxide Solution and easily oxidized materials; extreme temperature may initiate spontaneous combustion.

Observe the guidelines for performing quality control in medical laboratories by assaying controls and/or pooled sera. During handling of all kit reagents, controls and serum samples observe the existing legal regulations.

#### CONTENTS OF THE KIT

Package size	96 determ.
Qty.1	Divisible microplate consisting of 12 modules of 8 wells each, coated with highly purified human albumin. Ready to use.
6 vials, 0.5 ml each	Micro-Albumin-Calibrators (A-F) in a PBS/BSA matrix ( $\text{NaN}_3 <0,1\%$ (w/w)) containing micro-albumin: 0.15; 1.5; 6; 25; 100 and

	400 µg/ml. Ready to use.
2 vials, 0.5 ml each	Micro-Albumin Controls in a PBS/BSA matrix ( $\text{NaN}_3 <0,1\%$ (w/w)) positive (1) and negative (2), for the respective concentrations see the enclosed package insert. Ready to use.
1 vial, 10 ml	Sample buffer (Tris, $\text{NaN}_3 <0,1\%$ (w/w)), yellow. Ready to use.
1 vial, 15 ml	Enzyme conjugate solution (PBS, PROCLIN 300 $<0,5\%$ (v/v)), (light red) containing polyclonal rabbit anti-human albumin; labelled with horseradish peroxidase. Ready to use.
1 vial, 15 ml	TMB substrate solution. Ready to use.
1 vial, 15 ml	Stop solution (1 M hydrochloric acid). Ready to use.
1 vial, 20 ml	Wash solution (PBS, $\text{NaN}_3 <0,1\%$ (w/w)), concentrate (50x).

#### STORAGE AND STABILITY

1. Store the kit at 2-8 °C.
2. Keep microplate wells sealed in a dry bag with desiccants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light during storage and usage.
5. Diluted sample buffer and wash buffer are stable for at least 30 days when stored at 2-8 °C.

#### MATERIALS REQUIRED

##### Equipment

- Microplate reader capable of endpoint measurements at 450 nm
- Multi-Channel Dispenser or repeatable pipet for 100 µl
- Vortex mixer
- Pipets for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Data reduction software

##### Preparation of reagents

- Distilled or deionized water
- Graduated cylinder for 100 and 1000 ml
- Plastic container for storage of the wash solution

#### SPECIMEN COLLECTION, STORAGE AND HANDLING

1. Collect morning urine.
2. Samples may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to six months.

- Avoid repetitive freezing and thawing of urine samples. This may result in variable loss of albumin activity.
- Urine samples need not to be diluted. If higher concentrations are expected, samples should be diluted with sample buffer and dilutions considered during calculation.

#### PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots.
- All materials must be at room temperature (20-28 °C).
- Have all reagents and samples ready before start of the assay. Once started, the test must be performed without interruption to get the most reliable and consistent results.
- Perform the assay steps only in the order indicated.
- Always use fresh sample dilutions.
- Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover contamination change the tip between samples and different kit controls.
- It is important to wash microwells thoroughly and remove the last droplets of wash buffer to achieve best results.
- All incubation steps must be accurately timed.
- Control sera or pools should routinely be assayed as unknowns to check performance of the reagents and the assay.
- Do not re-use microplate wells.

For all controls, the respective concentrations are provided on the labels of each vial. Using these concentrations a calibration curve may be calculated to read off the patient results semi-quantitatively.

#### PREPARATION OF REAGENTS

##### Preparation of wash solution

Dilute the contents of each vial of the buffered wash solution concentrate (50x) with distilled or deionized water to a final volume of 1000 ml prior to use. Store refrigerated: stable at 2-8 °C for at least 30 days after preparation or until the expiration date printed on the label.

#### TEST PROCEDURE

- Prepare a sufficient number of microplate modules to accommodate calibrators, controls and patient samples in duplicates.

	1	2	3	4	5	6
A	SA	SE	P1	P5		
B	SA	SE	P1	P5		
C	SB	SF	P2	P..		
D	SB	SF	P2	P..		
E	SC	C1	P3			
F	SC	C1	P3			
G	SD	C2	P4			
H	SD	C2	P4			

SA - SF: standards A to F  
P1, P2... patient sample 1, 2 ...  
C1: positive control  
C2: negative control

- Pipet **20 µl** of calibrators, controls and undiluted patient samples into the wells.
- Add **100 µl** of enzyme conjugate solution into each well.
- Incubate for 30 minutes at room temperature (20 - 28 °C).
- Discard the contents of the microwells and wash 3 times with **300 µl** of wash solution.
- Dispense **100 µl** of TMB substrate solution into each well.
- Incubate for 15 minutes at room temperature.
- Add **100 µl** of stop solution to each well of the modules at leave untouched for 5 minutes.
- Read the optical density at 450 nm and calculate the results. Bi-chromatic measurement with a reference at 600 - 690 nm is recommended.

The developed colour is stable for at least 30 minutes. Read optical densities during this time.

#### Automation

The ORGENTEC Micro-Albumin ELISA is suitable for use on open automated ELISA processors. The test procedure detailed above is appropriate for use with or without automation.

#### INTERPRETATION OF RESULTS

##### Quality Control

This test is only valid if the optical density at 450 nm for Positive Control (1) and Negative Control (2) as well as for the Calibrator A and F complies with the respective range indicated on the Quality Control Certificate enclosed to each test kit ! If any of these criteria is not fulfilled, the results are invalid and the test should be repeated.

##### Calculation of results

For the Micro-Albumin test a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is recommended.

##### Manual Data Reduction: Recommended Lin-Log Plot

First calculate the averaged optical densities for each calibrator well. Use lin-log graph paper and plot the averaged optical density of each calibrator versus the concentration. Draw the best fitting curve approximating the path of all calibrator points. The calibrator points may

also be connected with straight line segments. The concentration of unknowns may then be estimated from the calibration curve by interpolation. The dilution of urine samples have to be considered.

### Calculation example

The figures below show typical results for Micro-Albumin ELISA. These data are intended for illustration only and should not be used to calculate results from another run.

Calibrators									
No	Position	OD 1	OD 2	Mean	Conc. 1	Conc. 2	Mean	decl.Conc.	CV %
STA	A 1/B 1	2.148	2.156	2,152	0.1	0.1	0.1	0.0	0
STB	C 1/D 1	1.748	1.746	1,747	1.5	1.5	1.5	1.5	0
STC	E 1/F 1	1.221	1.244	1,233	6.4	6.1	6.2	6.0	1
STD	G 1/H 1	0.700	0.687	0,694	23	24	24	25	1
STE	A 2/B 2	0.264	0.280	0,272	111	102	107	100	4
STF	C 2/D 2	0.098	0.091	0,094	368	396	382	400	5

### Interpretation of results

In a normal range study with urine samples from healthy donors the following range has been established with the Micro-Albumin test:

urine samples: 0 - 25 µg/ml Albumin

It is recommended that each laboratory establishes its own normal and pathological ranges of urine levels.

### PERFORMANCE CHARACTERISTICS

#### Parallelism

In dilution experiments urine samples with high Albumin concentrations were diluted with sample buffer and assayed in the Micro-Albumin kit. The assay showed linearity over the full measuring range.

#### Precision (Reproducibility)

Statistics were calculated for each of three samples from the results of 24 determinations in a single run for Intra-Assay precision. Run-to-run precision was calculated from the results of 5 different runs with 6 determinations each:

Intra-Assay		
Sample No	Mean [µg/ml]	CV [%]
1	25.2	5.3
2	50.9	3.3
3	80.2	3.6

Inter-Assay		
Sample No	Mean [µg/ml]	CV [%]
1	24.8	4.2
2	50.1	5.1
3	78.6	2.9

### Sensitivity

The lower detection limit for Micro-Albumin has been determined at 0.5 µg/ml.

### Specificity

The antisera (polyclonal, rabbit) labelled with horseradish peroxidase is highly specific for human Albumin.

### LIMITATIONS OF PROCEDURE

The Micro-Albumin ELISA is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated.

### REFERENCES

- Bretzel, R.G. Hypertonie, Mikroalbuminurie und Insulinresistenz bei Diabetes mellitus. Wiener Klin. Wochenschr. 1994; 106: 774 - 792.
- Diabetes and Endocrine Unit, Dudley Road Hospital, Birmingham, UK and Division of Community Health, Medical School, Guy's Hospital, London, UK. Microalbuminuria in type I diabetic patients. Prevalence and clinical characteristics. Microalbuminuria Collaborative Study Group. Diabetes Care 1992; 15: 495 - 501.
- Walker, J.D. et al. Glomerular structure in type-1 (insulin-dependent) diabetic patients with normo microalbuminuria. Kidn. Int. 1992; 41: 741 - 748.
- Mogensen, C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. New England J. Med. 1984; 310: 356 - 360.
- Gall, M.A. et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 655 - 661.
- Bashyam, M.M. et al. Microalbuminuria in NIDDM. Diabetes Care 1993; 16: 634 - 635.
- Caduff, F. et al. Erfassung der Mikroalbuminurie als Marker für die beginnende diabetische Nephropathie in der Praxis: welche Urinsammelmethode? Schweizerische Med. Wochenschr. 1991; 121: 324 - 331.
- Ruilope, L.M. et al. Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension. J. Hypert. Suppl. 1994; 12: S59 - S63.

## INCUBATION SCHEME

- 1 Pipet **20 µl** calibrator, control or patient sample,  
add **100 µl** enzyme conjugate
  - Incubate for **30 minutes** at room temperature
  - Discard the contents of the wells and wash 3 times with **300 µl** wash solution
- 2 Pipet **100 µl** substrate solution
  - Incubate for **15 minutes** at room temperature
- 3 Add **100 µl** stop solution
  - Leave untouched for **5 minutes**
  - Read at **450 nm**